Boston Medical Center chief honored by AUA

May 25, 2011

(Boston) - Richard K. Babayan, MD, chief of the Department of Urology at Boston Medical Center and Professor and Chairman of the Department of Urology at Boston University School of Medicine, was honored by the American Urological Association (AUA) at their annual meeting in Washington, DC, last week for his contributions to the field of medicine, the specialty of urology and the AUA.

Babayan received the Distinguished Service Award for outstanding service to the AUA Foundation, AUA Leadership Program and the AUA Board of Directors. "This award is testimony to the work of individuals who have made significant contributions to our subspecialty," said AUA Awards Committee Chair Paul F. Schellhammer, MD.

Babayan is a graduate of Indiana University School of Medicine and did his surgical training at Yale-New Haven Hospital before completing a urology residency at Boston University Medical Center in 1980. From 1980 - 1982, he was an American Urological Association Research Scholar performing basic science research in the field of hyperthermia at both MIT and BUSM. Babayan is a founding member of the Endourological Society and has been actively involved in minimally invasive therapies within the field of urology. His clinical interests center around benign prostatic hyperplasia, prostate cancer, urologic oncology, and endourology. Dr. Babayan performed the first robot assisted radical prostatectomy in Boston and is currently one of three urologic surgeons at BMC using the daVinci Robot for minimally invasive urologic procedures.

Dr. Babayan has been actively involved in local and national urologic organizations. He was the New England Section representative to the Board of Directors of the American Urological Association from 2005-2009. He is a Past President of the New England Section of the AUA and is a member of the Board of Directors of the Massachusetts Association of Practicing Urologists.
-end-
The American Urological Association was founded in 1902 and headquartered near Baltimore, Maryland. The AUA is the pre-eminent professional organization for urologists, with more than 16,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients.

Boston University Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.